Job Code 378MD
Fate Therapeutics is currently seeking a talented and highly motivated individual with a strong background in genomics and next generation sequencing (NGS) to join a multidisciplinary team dedicated to the discovery and characterization of novel induced pluripotent stem cell (iPSC)-derived cellular therapeutics. The candidate will play a foundational role in Fate’s Genomics team, providing genomic assay and data analysis support of characterizing Fate’s best-in-class iPSC-derived cellular therapies. The ideal candidate will be highly collaborative and communicative and have extensive hands-on experience in current genomics techniques including bulk and single-cell RNA sequencing, DNA sequencing, and related techniques associated with genomic, genetic, and epigenetic characterization of cells and tissues. The candidate will also be responsible for coordinating genomics core sample submission, tracking, and communicating deliverables. The position will require innovative thinking, strong independent and collaborative research abilities, a high level of organization, and the ability to communicate effectively across multidisciplinary teams. This is a full-time, bench-level position reporting to a Scientist, Genome Biology and is located at the Company’s corporate headquarters in San Diego, California.
Download a PDF of the job description for more details:
For consideration send cover letter and curriculum vitae to: email@example.com and reference job 378MD.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product candidate pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.